Prolongation of the insulinotropic action of glucagon-like peptide 1 by the dimethyl ester of succinic acid in an animal model of type-2 diabetes

被引:0
|
作者
García-Martínez, JA
Cancelas, J
Villanueva-Peñacarrillo, ML
Valverde, I
Malaisse, WJ
机构
[1] Free Univ Brussels, Expt Med Lab, B-1070 Brussels, Belgium
[2] Fdn Jimenez Diaz, E-28040 Madrid, Spain
关键词
succinic acid dimethyl ester; GLP-1; insulin release; type-2; diabetes;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Adult rats, that had been injected with streptozotocin during the neonatal period, received a primed constant infusion of succinic acid dimethyl ester (SAD; 0.5 mu mol followed by 0.25 mu mol . min(-1), both per g body wt.) in saline for 15 min and, at the 5th min of such an infusion, an intravenous injection of GLP-1 (5 pmol per g body wt.). Within 2 min, the ester increased the plasma insulin concentration by 0.33+/-0.05 nM. Likewise, within 2 min, GLP-1 provoked a marked increase in plasma insulin concentration; such an increase was comparable in rats infused with either saline or SAD, with an overall mean value of 0.93+/-0.07 nM. In the rats infused with SAD, however, the secretory response to GLP-1 appeared more sustained than in the saline-infused animals. For instance, the paired ratio for the insulinogenic index at 10/2 min after GLP-1 injection averaged 30.5+/-4.0% in SAD-infused rats, as compared (P<0.025) to only 17.0+/-2.5% in saline-infused animals. These findings suggest that succinic acid esters could be used to prolong the insulinotropic action of GLP-1 in the treatment of type-2 diabetes.
引用
收藏
页码:319 / 321
页数:3
相关论文
共 50 条
  • [21] Glucagon-like peptide-1 therapy for youth with type 2 diabetes
    Cho, Young Min
    JOURNAL OF DIABETES INVESTIGATION, 2023, 14 (03) : 362 - 363
  • [22] Glucagon-like peptide analogues for type 2 diabetes mellitus
    Shyangdan, Deepson S.
    Royle, Pamela
    Clar, Christine
    Sharma, Pawana
    Waugh, Norman
    Snaith, Alisa
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (10):
  • [23] Effectiveness of glucagon-like peptide-1 agonists in type 2 diabetes
    Pavlicek, Vojtech
    DIABETOLOGIE, 2023, 19 (03): : 359 - 360
  • [24] Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes
    Toft-Nielsen, MB
    Madsbad, S
    Holst, JJ
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (08): : 3853 - 3860
  • [25] New therapies for type 2 diabetes based on glucagon-like peptide 1
    Salehi, M
    D'Alessio, DA
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2006, 73 (04) : 382 - 389
  • [26] Therapeutics Glucagon-like peptide-1 analogues for type 2 diabetes
    Wilding, John P. H.
    Hardy, Kevin
    BRITISH MEDICAL JOURNAL, 2011, 342 : 433 - 435
  • [27] Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes
    Legakis, IN
    Tzioras, C
    Phenekos, C
    DIABETES CARE, 2003, 26 (01) : 252 - 252
  • [28] Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes
    Edwards, C. M. B.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2013, 74 (04) : 198 - 201
  • [29] Glucagon-like peptide-1 in type 2 diabetes:: the β-cell and beyond
    Nauck, Michael A.
    DIABETES OBESITY & METABOLISM, 2008, 10 : 2 - 13
  • [30] Evolutionary or revolutionary? The transformative role of glucagon-like peptide-1 agonists in type-2 diabetes management
    Bockwoldt, Denise
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 : S1 - S1